Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.
about
Antidrug Antibodies: B Cell Immunity Against TherapyImmune tolerance therapy dose as an outcome predictor.Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in IranEffect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors.Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.Application of current knowledge to the management of bleeding events during immune tolerance induction.Novel therapies for immune tolerance in haemophilia A.International workshop on immune tolerance induction: consensus recommendations.A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.Key issues in inhibitor management in patients with haemophilia.Clinical advances in hemophilia management.Immune tolerance induction for patients with severe hemophilia A: a critical literature review.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.More on: mild hemophilia A and inhibitor development.Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.Surgery in haemophilic patients with inhibitor: 20 years of experience.Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.How I manage patients with inherited haemophilia A and B and factor inhibitors.
P2860
Q28082303-E3D8B869-B9D8-4F6F-8301-864E73212622Q35163614-896E6253-6FD9-4737-9EC6-92DD0C330CC9Q35163649-0FFF5412-CD82-4035-8266-5C6FE170047BQ35602600-8601605C-C91C-4E04-A459-0C9038E0BA2EQ35782984-EEEABCF6-2CF2-4944-B517-685948EAB684Q36291064-3EAEEEA0-4638-46CB-8E5C-68CDFC4D7D9CQ36533453-11AA12CE-3C81-462F-9580-852B3E14CEEFQ36643874-6EB5647E-DD2B-4E88-9772-418D086C0D33Q36661858-3BEE62DA-0054-46D8-A43C-7FF5D93B5E53Q36861097-B1C54579-8A29-446C-A750-F9BAF5F6BEA6Q37124978-53F1FA82-BE05-4DF9-8C4E-F2FC44AC6636Q37394520-D7815DF1-254B-4542-8040-B3FEF7BF1A2BQ37602415-C3C74A4A-F4F3-47E6-B2F9-17767056629BQ37900933-E6207E6D-9544-45B6-BD30-9C6B19DBA2E1Q37912059-02E2FDEF-159C-4E73-B4FC-A68C4A42E89BQ37977140-83ACFE39-2EFB-47D7-9683-03B59C27D79BQ38222574-F367CC77-AB6F-4154-A2D3-E3DDB9684696Q38511360-2BB95C32-B105-4AFE-9755-3F2FA9AEB0EAQ38547840-6B9EF146-6AA6-4E3F-AFC6-8F3E087D9D1FQ38937408-4579C0F9-961A-4FC5-A060-A5630235CDDEQ45859168-79F8AB6C-D8FA-49A3-96F9-16E879982A37Q45874831-66B7B699-795E-4068-9F0D-FF163C011CABQ45878007-7BCE3418-1BFF-428D-97D2-04CE1069E7F8Q45878170-483D1302-0228-4030-9FF6-6D3ACACB6BB0Q45883398-BEE57DE1-EE3D-4588-9FE3-82E4B4C21349Q48359988-4282BBDA-DCC3-40F1-A1D4-0DBD5489295E
P2860
Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Induction of immune tolerance ...... therapy duration and outcome.
@en
Induction of immune tolerance ...... therapy duration and outcome.
@nl
type
label
Induction of immune tolerance ...... therapy duration and outcome.
@en
Induction of immune tolerance ...... therapy duration and outcome.
@nl
prefLabel
Induction of immune tolerance ...... therapy duration and outcome.
@en
Induction of immune tolerance ...... therapy duration and outcome.
@nl
P2093
P356
P1433
P1476
Induction of immune tolerance ...... therapy duration and outcome.
@en
P2093
H H Brackmann
J Oldenburg
P356
10.1159/000056717
P478
77 Suppl 1
P577
1999-01-01T00:00:00Z